Biotech Startups

Overture develops automation and technology to improve fertility treatment, aiming to lower costs and increase success rates. It targets the fertility care market and the people undergoing such treatment.

8 investors

P2 Science develops green chemistry platform technologies (including its PIOz ozonolysis and PICE polymerization processes) that convert renewable, plant-based oils into functional intermediates, specialty ingredients, and polymers. Its products serve the flavors, fragrances, and beauty/cosmetics industries, with R&D in Woodbridge, CT and manufacturing in Naugatuck, CT.

8 investors

Pear Bio delivers precision medicine tests and therapeutics for patients with hard-to-treat cancers by creating personalized treatment predictions from tumor biopsies and developing novel targeted therapies.

8 investors

Piramidal bridges in-vivo and in-silico intelligence for neuroscience research and clinical applications. The company develops technology that integrates biological data with computational intelligence.

8 investors

Prezent is an enterprise communication and presentation productivity platform powered by AI that helps teams increase communication effectiveness and reduce presentation production time and costs. The platform serves large organizations in the F2000.

8 investors

Prolific Machines licenses an optogenetics platform that adds light-based control to cell line development and GMP biomanufacturing, letting biopharma teams retrofit existing bioreactors and hosts to raise titers and manufacture complex molecule formats. It targets biopharmaceutical developers and manufacturers seeking higher productivity on difficult programs without re-platforming.

8 investors

Puna Bio develops microbial biostimulants, biofertilizers, and biofungicides for seed treatment based on extremophile bacteria collected from Argentina's Puna region, aimed at improving crop yields and regenerating degraded soils. Its products target crops such as soy, cotton, beans, wheat, and barley for the agricultural sector.

8 investors

Quartzy provides lab management software for life science research labs, helping researchers organize and manage lab supplies and inventory. It also offers procurement for scientific research teams.

8 investors

Rallybio is a clinical-stage biotech company developing therapies for people with severe and rare diseases, with a pipeline focused on complement dysregulation and hematology. It draws on its team's experience across drug discovery, research, development, manufacturing, and regulatory strategy to advance rare-disease drug candidates.

8 investors

Rejuvenate Bio develops gene therapy treatments aimed at the root causes of aging to address chronic, age-related conditions such as osteoarthritis, heart disease, and cancer. It targets both companion animals (particularly dogs) and humans.

8 investors

Remilk produces animal-free dairy by using microbial fermentation to recreate milk proteins identical to those in traditional dairy, without cholesterol, lactose, hormones, or antibiotics. The company targets the consumer food market with sustainable, cow-free dairy products.

8 investors

Rubi develops biotechnology solutions for sustainable manufacturing in the fashion and textiles industry. The company uses scientific innovation to reduce environmental impact from industrial manufacturing processes.

8 investors

Scipher Medicine is a precision immunology company that combines molecular data from autoimmune patients, protein interaction mapping, and AI to match patients with the most effective therapy for immunological diseases. Its offerings support therapy selection based on biomarkers and assist drug developers with research insights and commercialization analytics.

8 investors

Siren Biotechnology develops next-generation AAV (adeno-associated virus) platforms for gene therapy applications, including gene repair, gene transfer, and gene editing. The company focuses on advancing treatments for a wide range of rare diseases through engineered viral vectors and directed evolution approaches.

8 investors

Vestaron develops peptide-based insecticides derived from naturally-occurring peptides such as those found in spider venom, produced through fermentation, offering new modes of action for crop protection. Its SPEAR brand products target pests on high-value crops for growers in the agriculture and food industries with reduced impact on pollinators and the environment.

8 investors

Vincere Biosciences develops small-molecule therapeutics targeting mitochondrial quality control and mitophagy, primarily for neurodegenerative diseases including Parkinson's disease. The company translates computational biology and drug discovery into disease-modifying treatments for CNS disorders.

8 investors

VitalBio develops the VitalOne, a diagnostic device that delivers comprehensive lab-grade blood test results in minutes from a small blood sample, using robotics, biochemistry, computer vision, and microfluidics. It targets healthcare providers and patients seeking point-of-care diagnostic testing.

8 investors

AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA. The company targets diseases where the underlying genetic mechanism is well-established and difficult to address with existing therapeutic approaches.

8 investors

STRM.BIO develops technology to deliver gene therapies, aiming to improve how these treatments reach patients. The company operates in the biotech sector, focused on advancing gene therapy for patients worldwide.

7 investors

2AB BioscienceS develops first-in-class small molecule therapeutics targeting the 5-HT2A receptor for ophthalmology and central nervous system disorders. The platform uses structure-guided design to create therapies aimed at tissue regeneration, inflammation resolution, and neural circuit restoration.

7 investors

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis. The company is a clinical-stage biopharmaceutical firm running Phase 2/3 trials of its immunology treatments.

7 investors

ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes. It focuses on treatments for a range of diseases with unmet medical needs.

7 investors

Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology. Its lead candidate, ADCX-020, is being evaluated in a Phase 1 study in patients with advanced solid tumors.

7 investors

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism. The company's lead candidate, AV078, is a CNS-penetrant mTORC1 inhibitor in development for tuberous sclerosis complex refractory epilepsy.

7 investors